Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 6,656

Document Document Title
WO/2021/187679A1
The present invention relates to a composition, comprising a sea cucumber-derived saponin compound, for preventing, alleviating, or treating neuropathy. More specifically, the sea cucumber-derived saponin compound of the present inventio...  
WO/2021/183758A1
Defined herein are immunomodulating Formula (1) compounds wherein R, R0, R1, R2,R3 and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The inventi...  
WO/2021/183759A1
Defined herein are immunemodulating Formula (1) compounds wherein R1, R2, R3, and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention al...  
WO/2021/183762A1
Defined herein are immunomodulating Formula (1) compounds stereoisomers thereof, and pharmaceutically acceptable salts thereof; wherein R0, R1, R2, R10, W, Ring C and n are as defined herein, stereoisomers thereof, and pharmaceutically a...  
WO/2021/183754A1
Defined herein are immunomodulating Formula (1) compounds, wherein R1, R2 and W are as defined herein, stereoisomers thereof, and pharmaceutically acceptable salts thereof; and compositions comprising said compounds. The invention also i...  
WO/2021/172955A1
The present invention provides an intermediate useful for the synthesis of an SGLT inhibitor and a method for preparing an SGLT inhibitor using same. According to the present invention, by developing a compound of chemical formula 5 corr...  
WO/2021/169606A1
Disclosed in the present invention are an avermectin B2a ethylenic derivative, and a preparation method therefor and the use thereof. The structural formula of the avermectin B2a ethylenic derivative is as represented by formula I. The c...  
WO/2021/170621A1
The present invention relates to a biotechnological method for producing a C-glycoside of interest. The invention further relates to the use of a sialylated C-glycoside as a donor in an enzymatic glycosylation reaction. The present inven...  
WO/2021/160670A1
The present invention relates to a 3'-ketoglycoside compound defined by formula (I) and its use for controlled release of alcohols, in particular alcohols showing an insect repellent effect. It relates also to a process for preparing the...  
WO/2021/138847A1
Provided herein is macrolide compound and its use of treatment chronic respiratory disease. Specifically, it provides the compounds of formula (I) or pharmaceutically acceptable salts, stereoisomers and application thereof. The compounds...  
WO/2021/142312A1
Novel compositions comprising heparinoid-related compounds, manufacturing and treatment methods, kits and dosage forms thereof, are provided.  
WO/2021/131900A1
The purpose of the present invention is to provide a prenylflavonoid glycoside in which two or more hexoses have been bonded to isoxanthohumol or 8-prenylnaringenin, a method for producing the same, a method for producing a prenylflavono...  
WO/2021/122719A1
The present invention relates to a process for preparing a compound of formula (I), wherein said process is suitable for large scale synthesis.  
WO/2021/121362A1
Disclosed are a furaneol glycoside compound, a pharmaceutical composition thereof, a preparation method therefor, and an application thereof. Specifically disclosed are a compound as represented by formula A-1, a pharmaceutically accepta...  
WO/2021/113357A1
Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory dis...  
WO/2021/098843A1
An abamectin extraction method, comprising: performing extraction on abamectin residues using a dynamic ultrasonic extraction method, and concentrating the obtained liquid extract into extractum; performing extractive desugarization on t...  
WO/2021/081634A1
A combination that includes: a flavonoid, for example in an amount from about 0.1 g to about 1.5 g; and one or more of: ascorbic acid, ascorbate, or a combination thereof, for example in an amount from about 0.2 g to about 2.0 g; N-acety...  
WO/2021/085293A1
The present invention addresses the problem of providing an external skin preparation for ameliorating cellulite and a method for ameliorating cellulite, which can ameliorate cellulite in a simple manner without requiring special equipme...  
WO/2021/075904A1
The present invention relates to: a newly developed triazine-based amphiphilic compound; a preparation method therefor; and a method for extracting, lysing, stabilizing, crystallizing or analyzing membrane proteins by using same. In addi...  
WO/2021/062555A1
Topical formulations comprising one or more cannabinoids, one or more terpenes, and one or more flavonoids; and methods and uses thereof for the treatment of an integumentary wound, wherein the one or more cannabinoids comprise tetrahydr...  
WO/2021/062482A1
The invention relates to compounds that have antiviral activity, particularly 4-oxochromane derivatives that have antiviral activity against viruses of the Family Flaviviridae. Methods of treating viruses with the 4-oxochromane compounds...  
WO/2021/059058A1
A self-contained biological sterilization indicator comprises: a housing; bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of an enzyme substrate; and a frangible container containing a c...  
WO/2021/037077A1
Patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.  
WO/2021/031594A1
Disclosed are a novel aromatic ring compound represented by general formula (I), an isomer, a prodrug, a solvate, a pharmaceutically acceptable salt and a pharmaceutical composition thereof, and use thereof for preparing medicaments for ...  
WO/2021/030183A1
Disclosed are compositions comprising a polyene macrolide antibiotic and an azole antifungal, and packaged pharmaceutical products comprising the disclosed compositions. Also disclosed are methods of treating systemic fungal infections c...  
WO/2021/022690A1
The present invention relates to the field of chemical synthesis, in relates particular to a nucleoside salt represented by formula (III) or formula (IV), and a preparation method therefor. The method provided by the present invention is...  
WO/2021/025444A1
Despite various functions discovered of polyphenol-based compounds in regulating biological responses, such compounds, due to difficulty in procuring same in sufficient amounts with a high enough purity to permit application in pharmaceu...  
WO/2021/026450A1
Disclosed are C16 ester derivatives of C2'epi-amphotericin B (C2'epiAmB) characterized by improved clinical efficacy with reduced toxicity compared to AmB. Also disclosed are pharmaceutical compositions comprising the C 16 ester derivati...  
WO/2021/013155A1
Disclosed are a new glycosyl donor, a preparation method therefor, and an application thereof. Specifically, a glycosyl donor represented by formula (I), a preparation method therefor, and a use of the glycosyl donor represented by formu...  
WO/2021/008549A1
The present invention belongs to the field of pharmaceutical chemistry. Specifically, the present invention relates to a novel compound and a pharmaceutical composition. The novel compound has a structural formula represented by formula ...  
WO/2020/255865A1
[Problem] The objective of the present invention is to provide topical composition having a much higher whitening effect. [Solution] This topical composition, characterized by comprising (A) ascorbic acid and/or a derivative thereof, (B)...  
WO/2020/251862A1
The present invention provides methods and kits to improve the signal from sialic acids labeled with the dye 1, 2-diamino-4, 5-methylenedioxybenzene ("DMB"). The methods include labeling the sialic acids with DMB in an aqueous solution c...  
WO/2020/244148A1
The present application relates to a doramectin polymorph. Specifically, the present application relates to doramectin crystal form A, crystal form B, and a preparation method thereof. The polymorph can be obtained by dissolving doramect...  
WO/2020/244253A1
Disclosed is an application of a small molecule compound or a pharmaceutically acceptable salt thereof in the preparation of an anti-tumor metastasis drug. The structure of the compound is as shown in formula (I). The small molecule comp...  
WO/2020/241759A1
[Problem] To provide a novel medicine for preventing and/or treating influenza virus infection or corona virus infection. [Solution] According to the present invention, provided are an anti-influenza virus agent, an anti-corona virus age...  
WO/2020/238528A1
The invention relates to an intermediate TSL-1502M of a PARP inhibitor and a preparation method thereof. The structural formula of the intermediate is as shown. The preparation method includes the following step: under the action of sodi...  
WO/2020/212760A2
Described herein are compositions and methods for the treatment of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory/ infections disease of the anterior surface of the eye...  
WO/2020/198883A1
Transdermal medicaments containing cannabidiol (CBD) for use in the amelioration of conditions, including anxiety, depression, pain, inflammation, epilepsy, parkinson's disease, oxidative injury and nausea; and a method for preparing same.  
WO/2020/198578A1
The disclosure relates to methods of forming a dihydrochalcone using electrocatalytic dehydrogenation. In particular, the disclosure relates to methods of forming a dihydrochalcone electrocatalytically hydrogenating (ECH) a reactant comp...  
WO/2020/194237A1
Methods of rapidly inhibiting efflux from a cell, sensitizing a drug-resistant cell to a drug and treating a subject with a drug-resistant pathology, by administering tetrahydrocannabinolic acid (THCa), cannabidiol (CBD) or a combination...  
WO/2020/170840A1
The present invention addresses the problem of providing a novel crystal of 2-O-α-D-glucosyl-L-ascorbic acid and a method for producing the crystal. The problem is solved by providing a crystal of the potassium salt of 2-O-α-D-glucosyl...  
WO/2020/160443A1
Methods for preparing a polyene macrolide antifungal with improved aqueous solubility. The method involves providing a polyene macrolide antifungal having a carboxylic acid group; activating the carboxylic acid group; introducing a prima...  
WO/2020/132480A1
Compositions for treating an autoimmune, inflammatory, fibrotic, or proliferative disease or disorder comprising a compound that inhibits hyaluronan synthesis and a pharmaceutically acceptable carrier are described. In some embodiments, ...  
WO/2020/127843A1
The present disclosure relates to a compound of Formula (I): or anyone of its metabolites or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein each ...  
WO/2020/119773A1
The present disclosure relates to the field of medicine, and specifically relates to an amphotericin B peptide derivative and a preparation method therefor. The amphotericin B peptide derivative has a broad-spectrum and highly effective ...  
WO/2020/115661A1
A self-contained biological sterilization indicator comprises: a housing; bacterial spores comprising, and/or capable of producing, an enzyme capable of catalyzing cleavage of an enzyme substrate; and a frangible container containing a c...  
WO/2020/104697A1
The present invention relates to a synthetic saccharide of general formula (I) that is related to Clostridium difficile PS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical...  
WO/2020/106636A1
Provided are 13-membered macrolides for the treatment of infectious diseases. The 13- membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13-membered macrolides, pharmaceutical compositions ...  
WO/2020/106780A1
Provided herein are compounds or payloads, linker-payloads, antibody-drug conjugates, and compositions, and methods for the treatment of diseases and disorders associated with the liver X receptor, including bis-octahydrophenanthrene car...  
WO/2020/106627A1
Provided are 13-membered macrolides for the treatment of infectious diseases. The 13-membered macrolides described herein are azaketolides. Also provided are methods for preparing the 13- membered macrolides, pharmaceutical compositions ...  

Matches 1 - 50 out of 6,656